Pharmacovigilance and drug safety in Calabria (Italy): 2012 adverse events analysis

Journal of Pharmacology and Pharmacotherapeutics

Volumn 4, Issue SUPPL.1, 2013, Pages

  Giofrè, Chiara ^a,b   Scicchitano, Francesca ^a,b   Palleria, Caterina ^a,b   Mazzitello, Carmela ^a,b   Ciriaco, Miriam ^a,b   Gallelli, Luca ^a,b   Paletta, Laura ^a,b   Marrazzo, Giuseppina ^a,b   Leporini, Christian ^a,b   Ventrice, Pasquale ^a,b   Carbone, Claudia ^a,b   Saullo, Francesca ^a,b   Rende, Pierandrea ^a,b   Menniti, Michele ^a,b   Mumoli, Laura ^a,b   Chimirri, Serafina ^a,b   Patanè, Marinella ^a,b   Esposito, Stefania ^a,b   Cilurzo, Felisa ^a,b   Staltari, Orietta ^a,b   Russo, Emilio ^a,b   De Sarro, Giovambattista ^a,b   more..

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b Policlinico Mater Domini   (Italy)

Author keywords

Adverse drug reaction; Italy; ketoprofen; pharmacovigilance; safety

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; CARBAMAZEPINE; CEFTRIAXONE; DOCETAXEL; ETIRACETAM; KETOPROFEN; SORAFENIB; TOPIRAMATE; VALPROIC ACID;

ADOLESCENT; ADULT; AGED; ARTICLE; DATA BASE; DISEASE SEVERITY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FEMALE; HOSPITAL PHYSICIAN; HUMAN; INFORMATION CENTER; ITALY; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; MIDDLE AGED; POLYPHARMACY; SEX DIFFERENCE; STATISTICAL ANALYSIS; UNSPECIFIED SIDE EFFECT; YOUNG ADULT;

EID: 84889609516     PISSN: 0976500X     EISSN: None     Source Type: Journal    
DOI: 10.4103/0976-500X.120963     Document Type: Article

References (20)

1. World Health Organization. The Importance of Pharmacovigilance-Safety Monitoring of Medicinal Products. Geneva: World Health Organization; 2002. Available from: http://www.apps.who.int/medicinedocs/pdf/s4893e/s4893e.pdf. Last accessed 30th of April 2013.
2. International Drug Monitoring: The Role of National Centres (WHO) Technical Report Series No. 498. Geneva: World Health Organization; 1972.
3. Bankowski Z, Dunne JF, editors. Drug surveillance: International cooperation past, present and future. Proceedings of the XXVIIth CIOMS Conference. 14-15 September 1993. Geneva, Switzerland: CIOMS; 1994. p. 13-21.
4. Olsson S, Pal SN, Stergachis A, Couper M. Pharmacovigilance activities in 55 low-and middle-income countries: A questionnaire-based analysis. Drug Saf 2010;33:689-703.
5. Pal S, Dodoo A, Mantel A, Olsson S. Pharmacovigilance and Safety of Medicines. The World Medicines Situation 2011. 3rd ed. Geneva: WHO; 2011.
6. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies. JAMA 1998;279:1200-5.
7. Rambhade S, Chakarborty A, Shrivastava A, Patil UK, Rambhade A. A survey on polypharmacy and use of inappropriate medications. Toxicol Int 2012;19:68-73.
8. Strandell J, Norén GN, Hägg S. Key elements in adverse drug interaction safety signals: An assessment of individual case safety reports. Drug Saf 2013;36:63-70.
9. Gallelli L, Staltari O, Palleria C, Di Mizio G, De Sarro G, Caroleo B. A case of adverse drug reaction induced by dispensing error. J Forensic Leg Med 2012;19:497-8.
10. Patanè M, Ciriaco M, Chimirri S, Ursini F, Naty S, Grembiale RD, et al. Interactions among low dose of methotrexate and drugs used in the treatment of rheumatoid arthritis. Adv Pharmacol Sci 2013;2013:313858.
11. De Vuono A, Scicchitano F, Palleria C, Russo E, De Sarro G, Gallelli L. Lack of efficacy during the switch from brand to generic allopurinol. J Forensic Leg Med 2013;20:540-2.
12. De Vuono A, Palleria C, Scicchitano F, Squillace A, De Sarro G, Gallelli L. Development of skin rash during the treatment with generic itraconazole: Description of a case. J Pharmacol Pharmacother 2013 (In Press).
13. Sharma M, Gupta SK. Postmarketing surveillance. In: Gupta SK, editor. Textbook of Pharmacovigilance. New Delhi: Jaypee Brothers; 2011. p. 75-92.
14. Alj L, Touzani MD, Benkirane R, Edwards IR, Soulaymani R. Detecting medication errors in pharmacovigilance database: Capacities and limits. Int J Risk Saf Med 2007;19:187-94.
15. Härmark L, van Grootheest AC. Pharmacovigilance: Methods, recent developments and future perspectives. Eur J Clin Pharmacol 2008;64:743-52.
16. Clarke A, Deeks JJ, Shakir SA. An assessment of the publicly disseminated evidence of safety used in decisions to withdraw medicinal products from the UK and US markets. Drug Saf 2006;29:175-81.
17. WHO. WHO international drug monitoring: cerivastatin and gemfibrozil. WHO Drug Inf 2002;16:8-11.
18. Scicchitano F, Giofrè C, Palleria C, Mazzitello C, Ciriaco M, Gallelli L, et al. Pharmacovigilance and drug safety 2011 in Calabria (Italy): Adverse events analysis. J Res Med Sci 2012;17:872-5.
19. Lopez-Gonzalez E, Herdeiro MT, Figueiras A. Determinants of underreporting of adverse drug reactions: A systematic review. Drug Saf 2009;32:19-31.
20. Edwards IR. Pharmacovigilance. Br J Clin Pharmacol 2012;73:979-82.